Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 11/20 | 0.53 |
| ▸ | IGF1R | P08069 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.39 |
| ▸ | RHEB | Q15382 | 1/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.37 |
| ▸ | JAK2 | O60674 | 2/20 | 0.37 |
| ▸ | JAK1 | P23458 | 2/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | JAK3 | P52333 | 1/20 | 0.36 |
| ▸ | MGAM | O43451 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | SI | P14410 | 1/20 | 0.36 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3477023 | 0.93 | HRH4 (0.57) | HRH4KCNH2 | |
| SCHEMBL3477813 | 0.91 | HRH4 (0.63) | HRH4IGF1RCYP3A4CARM1RHEB | |
| SCHEMBL3477393 | 0.88 | HRH4 (0.63) | HRH4MGAMGAASIMGAM2 | |
| SCHEMBL3476972 | 0.87 | HRH4 (0.56) | HRH4IGF1RCYP3A4CARM1RHEB | |
| SCHEMBL602545 | 0.86 | HRH4 (0.55) | HRH4IGF1RCYP3A4RHEBADORA3 | |
| SCHEMBL3477458 | 0.84 | HRH4 (0.64) | HRH4KCNH2 | |
| SCHEMBL13338282 | 0.81 | HRH4 (0.49) | HRH4CARM1RHEBADORA3ADORA1 | |
| SCHEMBL3476926 | 0.79 | HRH4 (0.55) | HRH4CARM1RHEBKCNH2 | |
| Hydrochloric Acid SCHEMBL4480586 | 0.79 | HRH4 (0.55) | HRH4CARM1RHEBKCNH2 | |
| SCHEMBL604358 | 0.78 | HRH4 (0.55) | HRH4CARM1ADORA3ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2004188-B1 | BENZOIMIDAZOL-2-YL PYRIDINES AS MODULATORS OF THE HISTAMINE H4 RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2010-09-01 | — | — | EP | claimed |
| US-7589087-B2 | Benzoimidazol-2-yl pyridines as modulators of the histamine H4receptor | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-09-15 | — | — | US | claimed |
| JP-2009532367-A | — | — | 2009-09-10 | — | — | JP | claimed |
| EP-2004188-A4 | BENZOIMIDAZOL-2-YL PYRIDINES AS MODULATORS OF THE HISTAMINE H4 RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2009-04-22 | — | — | EP | claimed |
| EP-2004188-A2 | BENZOIMIDAZOL-2-YL PYRIDINES AS MODULATORS OF THE HISTAMINE H4 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-12-24 | — | — | EP | claimed |
| WO-2007117400-A2 | BENZOIMIDAZOL-2-YL PYRIDINES AS MODULATORS OF THE HISTAMINE H4 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-10-18 | — | — | WO | claimed |
| US-20070232616-A1 | Benzoimidazol-2-yl pyridines as modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-10-04 | — | — | US | claimed |
| EP-2004188-B1 | BENZOIMIDAZOL-2-YL PYRIDINES AS MODULATORS OF THE HISTAMINE H4 RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2010-09-01 | — | — | EP | disclosed |
| EP-2004188-B1 | BENZOIMIDAZOL-2-YL PYRIDINES AS MODULATORS OF THE HISTAMINE H4 RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2010-09-01 | — | — | EP | disclosed |
| US-7589087-B2 | Benzoimidazol-2-yl pyridines as modulators of the histamine H4receptor | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-09-15 | — | — | US | disclosed |
| US-7589087-B2 | Benzoimidazol-2-yl pyridines as modulators of the histamine H4receptor | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-09-15 | — | — | US | disclosed |
| US-7589087-B2 | Benzoimidazol-2-yl pyridines as modulators of the histamine H4receptor | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-09-15 | — | — | US | disclosed |
| WO-2007117400-A2 | BENZOIMIDAZOL-2-YL PYRIDINES AS MODULATORS OF THE HISTAMINE H4 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-10-18 | — | — | WO | disclosed |
| US-20070232616-A1 | Benzoimidazol-2-yl pyridines as modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-10-04 | — | — | US | disclosed |
| US-20070232616-A1 | Benzoimidazol-2-yl pyridines as modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-10-04 | — | — | US | disclosed |
| US-20070232616-A1 | Benzoimidazol-2-yl pyridines as modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232616-A1 | Benzoimidazol-2-yl pyridines as modulators of the histamine H4 receptor | HRH4, HRH3, HRH2 | HRH4 1/4885IGF1R 2213/4885CYP3A4 1757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.